BioCentury: Orexo is Dissolving Away Opioid Addiction with New Medication

Orexo is an emerging specialty pharmaceutical company in route to enter the market with their new medication Zubsolv; an oral medication that dissolves under the tongue to treat opioid addiction.

Read more »

Metabiomics’ Exec: Test Can Be a Cheaper and More Accurate Alternative to Colonoscopies

Metabiomics is developing a noninvasive screening test for colon polyps in colorectal cancer based on human microbiome markers. In an interview with OneMedRadio, Gregory Kuehn, Vice President of Business Development at Metabiomics, explained that the preliminary data showed “sensitivity in excess of 97%” and specificity “as high as 93%.” Metabiomics will present at the upcoming OneMedForumNY 2013 on June 27th.

Read more »

Can Avastin’s Shortcomings Open the Door for Del Mar Pharmaceuticals?

The effectiveness of Genentech and Roche’s (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin’s approval for treating GBM.

Read more »

Bioinformatics Part II: Application, Manipulation, and Uses

Or, How I Learned to Stop Worrying and Love Computational Biology.

Read more »

Cyto Wave Technologies CEO: First Device to Detect Circulating Tumor Cells In Vivo

Cyto Wave Technologies’ iV3 device can detect circulating tumor cells in real time via laser technology and potentially destroy cells. OneMedRadio spoke with Cyto Wave Technologies President and CEO George Yu about the favorable on-ramp to commercialization, clearing regulatory and reimbursement obstacles and the vast opportunity for in vivo CTC detection.

Read more »

RELEASE: Mercator MedSystems Raises Additional $6.5 Million

Mercator MedSystems, Inc., a privately-held medical technology company reinventing the treatment of disease deep inside the body, today announced the closing of a $6.5 million Series B financing. The funding will be used to initiate sales of its Cricket™ and Bullfrog® Micro-Infusion devices in Europe, the United States and Australia.

Read more »

Zacks: Peregrine Pharma – On the Verge of Releasing First Oncology Drug to Market

Peregrine Pharma (PPHM) recently announced that the US. Food and Drug Administration (FDA) has approved on the design for their Phase III registration trial for its oncology drug, Bavituximab.

Read more »

Motley Fool: Oncolytics – Cancer Killing Virus enters Phase II Metastatic Melanoma Trial

A unique drug is on the right pathway to success, as Oncolytics Biotechnology (ONCY) is pushing Reolysin through the pipeline. David Williamson from Motley Fool reported that this cancer medication is based off a common virus, incidentally referred to as the new “Cancer-Killing Virus.”

Read more »

Biocentury: AVEO’s FDA Woes for Renal Cell Carcinoma Drug stops Astella’s Funding

AVEO Pharmaceuticals’ (AVEO) New Drug Application (NDA) with the FDA for their newly developed once a day oral medication to fight advanced renal cell carcinoma – known as Tivozanib – has hit a snag.Upon review, the FDA’s Oncologic Drugs Advisory Committee voted 13-1 against approval due to safety concerns.

Read more »

MAPPING THE B.R.A.I.N.

On April 2nd, 2013, U.S. President Barack Obama unveiled the “BRAIN” Initiative, which is short for Brain Research through Advancing Innovative Neurotechnologies. The BRAIN Initiative may be known as the spiritual successor to the Human Genome Project, not only for its desire to understand a mysterious place known to medical science, but for taking its cues from the initial success of the HGP.

Read more »